Randomized Phase 2 trial of Isatuximab during Autologous Stem Cell Collection and transplantation Period in patients with Multiple Myeloma and Lymphoma (Multiple Myeloma)
Study of Isatuximab in Patients with Multiple Myeloma or Lymphoma who are Recovering from Stem Cell Transplant
Sponsor: Sanofi Genzyme
Enrolling: Male and Female Patients
IRB Number: AAAT7444
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm), Participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each Participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
This study is closed
Investigator
Divaya Bhutani, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with multiple myeloma or lymphoma? Yes No
Have you gone through/currently going through stem cell transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162